GRI Bio, Inc.
GRI$2M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLA JOLLA
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
AI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Tazarotene (GRI-0621) | Phase 2 | Idiopathic Pulmonary Fibrosis | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
GRI News